Ignite Creation Date:
2024-05-06 @ 4:59 PM
Last Modification Date:
2024-10-26 @ 2:20 PM
Study NCT ID:
NCT05156788
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2023-08-15
First Post:
2021-09-30
Brief Title:
TislelizumabAnti PD-1 Lenvatinib and GEMOX Transformation in the Treatment of Potentially Resectable Locally Advanced Biliary Tract Cancer
Sponsor:
Shanghai Zhongshan Hospital
Organization:
Shanghai Zhongshan Hospital
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Lenvatinib |
| Biliary Tract Cancer |
| PD-1 Antibody |
| Gemox |
Keywords: